 Rehovot, Israel, March 03, 2021 GLOBE NEWSWIRE -- Purple Biotech Ltd. Purple Biotech NASDAQTASE: PPBT, a clinical-stage company developing first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Robert Gagnon to its Board of Directors. Mr. Gagnon has 15 years of experience in corporate finance and commercial operations, much of it in the biotech industry. Purple Biotechs Board of Directors now includes seven members, five of whom are independent directors. Mr. Gagnon shall serve as a member of the first class of the Board of Directors until the annual general meeting of shareholders to be held in 2022, at which time he may stand for reelection. 